Inflammation Drug Fails to Cut Heart Risk in Kidney Patients
A large Novo Nordisk trial hit its biological target in very sick patients, but the payoff researchers hoped for did not follow.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Ziltivekimab, a Novo Nordisk antibody that blocks the inflammatory protein interleukin-6, failed to reduce heart attacks, strokes, or deaths from heart disease among adults who…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.